Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 37 (3) , 109870
Abstract
No abstract availableKeywords
Funding Information
- Howard Hughes Medical Institute
- National Institutes of Health (R35-GM136250)
- National Institutes of Health (R01-CA76584)
- National Institutes of Health (2T32CA009161)
- National Research Council (70126)
- LAM Therapeutics
This publication has 75 references indexed in Scilit:
- FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomasNature, 2012
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Control of cell growth by the SCF and APC/C ubiquitin ligasesCurrent Opinion in Cell Biology, 2009
- Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineagesNature Chemical Biology, 2009
- F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damageNature, 2009
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Three-dimensional culture models of normal and malignant breast epithelial cellsNature Methods, 2007
- A module of negative feedback regulators defines growth factor signalingNature Genetics, 2007
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994